• 한국융합학회논문지
• /
• 제10권3호
• /
• pp.23-30
• /
• 2019

본 연구는 당뇨병 치료제 후보약물 정보를 이용하여 항당뇨에 영향을 미치는 물질구조를 발견하는데 목적이 있다. 정량적구조 활성관계를 이용한 기계 학습 모델을 만들고 부분최소자승 알고리즘을 통해 실험데이터 별로 결정계수를 파악한 후 변수중요도척도를 활용하여 주요 분자표현자를 도출하였다. 연구 결과, 후보약물 구조정보를 반영한 molecular access system fingerprint 데이터로 분석한 결과가 in vitro 데이터를 이용한 분석 결과보다 설명력이 높았으며, 항당뇨에 영향을 미치는 주요 분자표현자 역시 다양하게 도출할 수 있었다. 제안된 항당뇨 예측 및 주요인자 분석 방법을 활용한다면 유사한 과정을 반복 실험하는 기존 신약개발 방식과는 달리, 많은 비용과 시간이 소요되는 후보물질 스크리닝 (screening) 기간을 최소화하고, 신약개발 탐색기간도 단축하는 계기가 될 수 있을 것으로 기대한다.

• Journal of Obesity & Metabolic Syndrome
• /
• 제27권4호
• /
• pp.238-247
• /
• 2018

Background: We aimed to estimate the proportion of patients with diabetes who achieved target glycemic control, to estimate diabetes-related costs attributable to poor control, and to identify factors associated with them in the United Arab Emirates. Methods: This retrospective cohort study used administrative claims data handled by Abu Dhabi Health Authority (January 2010 to June 2012) to determine glycemic control and diabetes-related treatment costs. A total of 4,058 patients were matched using propensity scores to eliminate selection bias between patients with glycosylated hemoglobin (HbA1c) <7% and HbA1c ${\geq}7%$. Diabetes-related costs attributable to poor control were estimated using a recycled prediction method. Factors associated with glycemic control were investigated using logistic regression and factors associated with these costs were identified using a generalized linear model. Results: During the 1-year follow-up period, 46.6% of the patients achieved HbA1c <7%. Older age, female sex, better insurance coverage, non-use of insulin in the index diagnosis month, and non-use of antidiabetic medications during the follow-up period were significantly associated with improved glycemic control. The mean diabetes-related annual costs were $2,282 and $2,667 for patients with and without glycemic control, respectively, and the cost attributable to poor glycemic control was $172 (95% confidence interval [CI], $164-180). The diabetes-related costs were lower with mean HbA1c levels <7% (cost ratio, 0.94; 95% CI, 0.88-0.99). The costs were significantly higher in patients aged ${\geq}65$ years than those aged ${\leq}44$ years (cost ratio, 1.45; 95% CI, 1.25-1.70). Conclusion: More than 50% of patients with diabetes had poorly controlled HbA1c. Poor glycemic control may increase diabetes-related costs.